Seres Therapeutics, Inc. (MCRB)
5.28
-0.28
(-5.04%)
USD |
NASDAQ |
Sep 09, 16:00
5.45
+0.17
(+3.22%)
After-Hours: 20:00
Seres Therapeutics Enterprise Value : 95.69M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 95.69M |
| September 04, 2026 | 97.26M |
| September 03, 2026 | 96.48M |
| September 02, 2026 | 95.49M |
| September 01, 2026 | 91.96M |
| August 31, 2026 | 89.30M |
| August 28, 2026 | 91.27M |
| August 27, 2026 | 89.70M |
| August 26, 2026 | 87.83M |
| August 25, 2026 | 90.19M |
| August 24, 2026 | 86.85M |
| August 21, 2026 | 85.86M |
| August 20, 2026 | 85.96M |
| August 19, 2026 | 87.04M |
| August 18, 2026 | 83.70M |
| August 17, 2026 | 85.37M |
| August 14, 2026 | 85.67M |
| August 13, 2026 | 85.08M |
| August 12, 2026 | 87.44M |
| August 11, 2026 | 86.65M |
| August 10, 2026 | 90.19M |
| August 07, 2026 | 88.91M |
| August 06, 2026 | 88.42M |
| August 05, 2026 | 90.24M |
| August 04, 2026 | 92.64M |
| Date | Value |
|---|---|
| August 03, 2026 | 90.48M |
| July 31, 2026 | 88.52M |
| July 30, 2026 | 88.03M |
| July 29, 2026 | 86.75M |
| July 28, 2026 | 88.22M |
| July 27, 2026 | 88.71M |
| July 24, 2026 | 89.84M |
| July 23, 2026 | 92.45M |
| July 22, 2026 | 92.94M |
| July 21, 2026 | 92.64M |
| July 20, 2026 | 91.27M |
| July 17, 2026 | 93.43M |
| July 16, 2026 | 91.96M |
| July 15, 2026 | 94.61M |
| July 14, 2026 | 93.48M |
| July 13, 2026 | 96.28M |
| July 10, 2026 | 101.10M |
| July 09, 2026 | 107.29M |
| July 08, 2026 | 111.22M |
| July 07, 2026 | 121.05M |
| July 06, 2026 | 116.82M |
| July 02, 2026 | 117.12M |
| July 01, 2026 | 119.08M |
| June 30, 2026 | 118.59M |
| June 29, 2026 | 125.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.581M |
| Revenue (Quarterly) | 0.736M |
| Total Expenses (Quarterly) | -3.845M |
| EPS Diluted (Quarterly) | 0.47 |
| Gross Profit Margin (Quarterly) | 8.97% |
| Earnings Yield | -43.13% |
| Normalized Earnings Yield | -33.70 |